N/A N=33 Memory Consolidation in Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Overnight Change in Declarative Memory Performance — 11.2; 6.5 percent change in performance
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
Recurrent Melanoma · Stage IA Skin Melanoma · Stage IB Skin Melanoma
Primary: Percentage of Participants With Successful Intravital Microscopy on Accessible Human Melanoma Tumors During Standard Local Excision — 70 percentage of participants
Phase 4 N=30 Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit
Atopic Dermatitis
Primary: Adherence — 56; 72 percentage of required applicaitons
Early Phase 1 N=146 Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
Lung Cancer · Tobacco Use Disorder · Breast Cancer
Primary: Feasibility of a Smoking Cessation Intervention Among Cancer Patients — 55; 33 Participants
Phase 2 N=167 Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
Breast Cancer
Primary: Pathological Tumor Response to Neoadjuvant Chemotherapy (Taxotere and AC) — 3; 9; 2; 1 participants
N/A N=30 Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome
Respiratory Distress Syndrome
Primary: Change From Baseline in Blood C-reactive (CRP) Protein — 1.300; 0.193 mg/dL — p=<.05
Phase 2 N=636 A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children
Dengue Fever · Dengue Hemorrhagic Fever · Dengue Shock Syndrome
Primary: Safety: Incidence of All and Grade 3 Solicited Local Symptoms — 114; 98; 84; 55 number of occurances
Phase 2 N=34 Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Percent of Patients Who Complete an Accelerated Infusion Regimen Within 15 Minutes of the Planned 2-hour Treatment. — 84 percentage of participants
Phase 2 N=80 Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Prostate Cancer
Primary: Number of Participants Free From Progression at 3 Years — 54 participants
N/A N=12 Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study
Papillary Carcinoma of Thyroid Gland · Metastatic Medullary Thyroid Cancer · Follicular Thyroid Cancer Lymph Node Metastasis
Primary: Primary Efficacy Parameters of Sensitivity of High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles (LSN MRI) — 85.5 percentage…
Phase 2 N=172 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Complete Response Rate — 76; 24 participants
Phase 4 N=198 A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Exercise Endurance Time (EET) Post-dose at Week 12 of Each Treatment Period — -2.06; -5.37 Seconds (s) — p=0.790
Phase 2 N=25 Safety and Effect of Doxycycline in Patients With Amyloidosis
Amyloidosis
Primary: Amyloid Cardiomyopathy: BNP — 883 pg/mL — p=0.035
N/A N=132 Accuracy of Noninvasive Hemoglobin Pulse Oximeter (Rainbow Resposable Adhesive Sensors)
Healthy
Primary: Accuracy of Sensor by Arms Calculation — 1.0 g/dL
Phase 2 N=116 Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
Leukemia
Primary: Percentage of Participants With Overall Response Rate (ORR) — 59.6 Percentage of participants — p=<0.001